home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> biomedical companies   |   search    |   registration     |   modification  
 

registry of biomedical companies

 
  October 23, 2021
promoting the transfer of scientific know-how between industry and academia
 
 
Registry of biomedical companies:

[3] [7] [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 468 active entries

Synport Infocommunications Canada

1440 Barberry Dr.
Port Coquitlam
Canada
Toll free: +011-604-941-9022 (Helpline)

Phone: 16049458408
Fax: +011-604-941-9022
E-Mail: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

Description:

Our Principal has pioneered the concept of transmembrane/compartmentalized processing as applied to animalia through process innovation, modeling for innovation and in vivo/ex vivo direct studies in the ff. areas or fields of study available through the literature:

a) Peptide Nucleic Acid Technology for gene silencing using transcription factor "engineering" (TFE) using transport carriers or porins in microbial cell systems in the rumen stomach of livestock for peptides/amino acids which could spell an advantage in accelerating intracellular transactions both for low concentration free amino acids released through proteolysis at various rates of availability depending on substrate from the animal's diet and/or peptides also made available through digestion that have an effect on microbial cell protein (MCP) synthesis per energy unit (ATP) used (cf. to free amino acids).

b) We have discussed before (see in this portal outlet: Medica & Communications3) elsewhere possible significant advances for cholesterol fighting drugs using PNA Technology through TFE due to compartmentalization of cholesterol flux or titre in bodily fluids in this case in chicken or poultry (e. g. turkeys) shell egg cholesterol storage due to cholesterol transport/esterase activity with the yolk sac and so with the pancreas as it deposits cholesterol ester derivatives as bile into the lower gut effectively lowering bad HDL cholesterol in bodily plasma fluid. These represent two potential areas for further development in controlling cholesterol levels in the body of animalia through our use of simple modeling.

c) Hormones, neurhormones or peptides, vitamins (e. g. VitD) and immunopeptides are all addressable using our PNA Technology through TFE and porins or receptors which would be "gentler" rather than other drug or pharma acting directly on those agents mentioned previously taking their given pool size as such and the boost in porin / receptor pool size in target cell populations. These applications entail addressing reproductive, developmental  or growth, occupationally-related or health-related disorders like chronic inflammation (cf. T2Di abetes atherosclerosis, cancers, multiple sclerosis), and immunomodulation in immune functions in animalia including humans.

 

(c) D. A. Flores. SKYE BLUE INTERNET. Port Coquitlam. B. C. Canada V3B 1G3.



Selected Categories:
Product Company   Service Company
Contract
- Services
Professional
- Communications

Last update of this entry: August 01, 2021

   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by companies 4.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2021 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.